for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TORII PHARMACEUTICAL CO., LTD.

4551.T

Latest Trade

2,748.00JPY

Change

-2.00(-0.07%)

Volume

56,200

Today's Range

2,706.00

 - 

2,756.00

52 Week Range

2,067.00

 - 

3,035.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,750.00
Open
2,741.00
Volume
56,200
3M AVG Volume
1.32
Today's High
2,756.00
Today's Low
2,706.00
52 Week High
3,035.00
52 Week Low
2,067.00
Shares Out (MIL)
28.07
Market Cap (MIL)
79,142.40
Forward P/E
3.30
Dividend (Yield %)
1.75

Next Event

Q3 2019 Torii Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1

Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan

Torii Pharmaceutical Co Goichi Matsuda To Be President Effective March 26

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TORII PHARMACEUTICAL CO., LTD.

TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. Its products include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, psoriasis vulgaris treatment agents, antifungal drugs, anti-HIV drugs and antiflatulents, among others. JAPAN TOBACCO INC. (JT) is the parent company of the Company.

Industry

Biotechnology & Drugs

Contact Info

Torii Nihonbashi Bldg.

3-4-1, Nihonbashi-Honcho

+81.3.32316811

https://www.torii.co.jp/

Executive Leadership

Shoichiro Takagi

President, Representative Director

Ken Yamamoto

Executive Officer, Director of Accounting & Finance

Akihiko Tamura

Managing Director

Takahiro Umeda

Managing Director, Leader of Planning & Support Group

Nobumasa Kondo

Executive Officer, Leader of Planning & Support Group

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, JPY)
EPS (JPY)
Price To Earnings (TTM)
2.99
Price To Sales (TTM)
1.50
Price To Book (MRQ)
0.68
Price To Cash Flow (TTM)
2.95
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
25.23
Return on Equity (TTM)
20.47

Latest News

Latest News

BRIEF-Torii Pharmaceutical says new drug application approval of allergen immunotherapy tablet for japanese cedar pollinosis

* Says the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of "CEDARCURE® Japanese Cedar Pollen Sublingual Tablets", an allergen immunotherapy tablet for Japanese cedar pollinosis

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up